Core Viewpoint - The company, Zhaoke Ophthalmology-B (6622.HK), has seen a significant stock price increase of 17.36%, reaching HKD 3.65, potentially marking a new closing high since January 4, 2024 [1] Group 1: Product Development - The company has obtained a medical device registration certificate for TONO-i from the National Medical Products Administration, which will be a key part of its glaucoma product portfolio [1] - TONO-i aims to address the demand gap in China for low diagnosis and treatment rates in glaucoma management, indicating the company's commitment to dual approaches in treatment and diagnosis [1] Group 2: Strategic Partnerships - In November 2022, the company entered into an exclusive distribution agreement with C&VTech, a leading company in the development of medical devices for the diagnosis, treatment, and prevention of glaucoma [1] - The agreement grants the company exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, with rights later expanded to include Thailand and Malaysia, effective from August 2024 [1]
港股异动丨兆科眼科-B大涨17% 有望创逾一年半收盘新高